Additionally, Maas Biolab LLC, NeuroVive’s largest shareholder, has undertaken to donate for free and transfer a total of approx. 2 million subscription rights to Baulos Capital and Dr. Guo Weicheng, which Baulos Capital and Dr. Guo Weicheng have undertaken to subscribe for.
Overall, this means a commitment by Baulos Capital to subscribe for 595,000 shares, or approx. SEK 8.3 m, and by Dr. Guo Weicheng a commitment to subscribe for 358,250 shares, or approx. SEK 5 m in the rights share issue.
The subscription period for NeuroVive’s current rights share issue continues until 27 January 2014 and is open to current and new investors and shareholders. More information about the right share issue including video interviews and application forms are available at http://neurovive.irportalen.se/?lang=en
NeuroVive Pharmaceutical AB (publ) is a leading mitochondrial medicine company that is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These conditions are characterized by substantial patient need and the absence of approved pharmaceutical treatments at present. NeuroVive’s products, CicloMulsion® (myocardial infarction) and NeuroSTAT® (traumatic brain injury), are currently in phase III and phase II studies respectively. NeuroVive’s research also encompasses products for the treatment of antiviral indications (Hepatitis B/C), injuries to brain cells in stroke and candidate drugs providing neuroprotection and energy regulation in mitochondrial disease. NeuroVive is listed on NASDAQ OMX Stockholm.
For Investor Relations and media questions, please contact:
Ingmar Rentzhog, Laika Consulting, tel: +46 (0)46 275 62 21 or firstname.lastname@example.org
It is also possible to arrange an interview with NeuroVive’s CEO Mikael Brönnegård at the above contact.
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: + 46 (0)46 888 83 48
NeuroVive Pharmaceutical AB (publ) is required to publish the information in this press release under The Swedish Securities Market Act. The information was submitted for publication on 23 January 2014, at 16:20 CEST